STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
Vladmir Cláudio Cordeiro de Lima, Marcelo Corassa, Erick Figueiredo Saldanha, H. Freitas, Óscar Arrieta, Luis E. Raez, Suraj Samtani, Maritza Ramos-Ramírez, Carlos A. Rojas, Mauricio Burotto, Diego F. Chamorro, Gonzalo Recondo, Alejandro Ruíz-Patiño, Luís Más, Lucía Zatarain-Barrón, Sergio Mejía, José Nicolas Minata, Claudio Martín, Juan Bautista Blaquier, Rodrigo Motta, Carlos Aliaga-Macha, Carlos Carracedo, Camila Ordóñez- Reyes, Juan Esteban García-Robledo, Luis Corrales, Carolina Sotelo, Luisa Ricaurte, Nicolás Santoyo, Mauricio Cuello, Elvira Jaller, July Rodríguez, Pilar Archila, Maritza Bermúdez, Tatiana Gámez, Alessandro Russo, Lucía Viola, Umberto Malapelle, Diego de Miguel‐Pérez, Christian Rolfo, Rafael Rosell, Andrés F. Cardona
Abstract
BACKGROUND: ) are associated with poor survival in metastatic Non-small Cell Lung Cancer (mNSCLC) patients treated with immunotherapy. However, there are limited data regarding the prognostic or predictive significance of these genomic alterations among Hispanics. METHODS: population, historical data from a cohort of Hispanic patients (N = 101) treated with first-line ICI was used, matching both groups by country of origin, gender, and Programed Death-ligand 1 (PD-L1) expression level (Cohort B). RESULTS: 24.4 months (p = 0.005)] mutations. PD-L1 expression significantly affected OS independently of the presence of mutations in STK11, KEAP1, or KRAS. TMB-H favored better OS. CONCLUSIONS: This is the first large Hispanic cohort to study the impact of STK11 and KEAP1 mutations in NSCLC patient treated with ICI. Our data suggest that mutations in the above-mentioned genes are associated with PD-L1 expression levels and poor OS.